Featured Research

from universities, journals, and other organizations

Finding keys to glioblastoma therapeutic resistance

Date:
August 25, 2014
Source:
University of California, San Diego Health Sciences
Summary:
One of the keys to why certain glioblastomas – the primary form of a deadly brain cancer – are resistant to drug therapy has been found by researchers. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature, they report.

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas -- the primary form of a deadly brain cancer -- are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.

Related Articles


"There is a growing interest to guide cancer therapy by sequencing the DNA of the cancer cell," said Clark Chen, MD, PhD, vice-chairman of Research and Academic Development, UC San Diego Division of Neurosurgery and the principal investigator of the study. "Our study demonstrates that the sensitivity of glioblastoma to a drug is influenced not only by the content of its DNA sequences, but also by how the DNA sequences are organized and interpreted by the cell."

The team of scientists, led by Chen, used a method called comparative gene signature analysis to study the genetic profiles of tumor specimens collected from approximately 900 glioblastoma patients. The method allows investigators to discriminate whether specific cellular processes are "turned on" or "turned off" in glioblastomas. "Our study showed that not all glioblastomas are the same. We were able to classify glioblastomas based on the type of cellular processes that the cancer cells used to drive tumor growth," said Jie Li, PhD, senior postdoctoral researcher in the Center for Theoretical and Applied Neuro-Oncology at UC San Diego and co-first author of the paper.

One of these cellular processes involves Epidermal Growth Factor Receptor (EGFR). The study revealed that EGFR signaling is suppressed in a subset of glioblastomas. Importantly, this suppression is not the result of altered DNA sequences or mutations. Instead, EGFR is turned off as a result of how the DNA encoding the EGFR gene is organized in the cancer cell. This form of regulation is termed "epigenetic." Because EGFR is turned off in these glioblastomas, they become insensitive to drugs designed to inhibit EGFR signaling.

"Our research suggests that the selection of appropriate therapies for our brain tumor patients will require a meaningful synthesis of genetic and epigenetic information derived from the cancer cell," said co-first author Zachary J. Taich.

The paper's abstract can be found at: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=2350


Story Source:

The above story is based on materials provided by University of California, San Diego Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Clark C. Chen et al. Epigenetic suppression of EGFR signaling in G-CIMP glioblastomas. Oncotarget, August 2014

Cite This Page:

University of California, San Diego Health Sciences. "Finding keys to glioblastoma therapeutic resistance." ScienceDaily. ScienceDaily, 25 August 2014. <www.sciencedaily.com/releases/2014/08/140825185321.htm>.
University of California, San Diego Health Sciences. (2014, August 25). Finding keys to glioblastoma therapeutic resistance. ScienceDaily. Retrieved April 21, 2015 from www.sciencedaily.com/releases/2014/08/140825185321.htm
University of California, San Diego Health Sciences. "Finding keys to glioblastoma therapeutic resistance." ScienceDaily. www.sciencedaily.com/releases/2014/08/140825185321.htm (accessed April 21, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, April 21, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Teva Offers $40 Billion for Mylan

Teva Offers $40 Billion for Mylan

Reuters - Business Video Online (Apr. 21, 2015) Generic drugmaker Teva Pharmaceutical is offering $82 a share, or $40 billion, for its smaller rival Mylan, in an alternative to Mylan&apos;s deal to buy Perrigo. Bobbi Rebell reports. Video provided by Reuters
Powered by NewsLook.com
Blue Bell Recalls All Products

Blue Bell Recalls All Products

AP (Apr. 21, 2015) Blue Bell Creameries voluntary recalled for all of its products after two samples of chocolate chip cookie dough ice cream tested positive for listeria, a potentially deadly bacteria. Blue Bell&apos;s President and CEO issued a video statement. (April 21) Video provided by AP
Powered by NewsLook.com
Yemen Doctors at Breaking Point

Yemen Doctors at Breaking Point

Reuters - News Video Online (Apr. 21, 2015) A Sanaa hospital struggles to cope with the high number of casualties with severe injuries, after an air strike left at least 25 dead and hundreds wounded. Deborah Lutterbeck reports. Video provided by Reuters
Powered by NewsLook.com
'Tutu Tuesdays' Brighten Faces at Kids' Hospital

'Tutu Tuesdays' Brighten Faces at Kids' Hospital

AP (Apr. 21, 2015) Doctors and nurses have started wearing ballet tutus every Tuesday to cheer up young hospital patients at a Florida hospital. It started with a request made by a nervous patient -- now, almost the entire staff is wearing the tutus. (April 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins